Meeting
2021 ASCO Annual Meeting
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.
Authors
Evangelos Terpos
National and Kapodistrian University of Athens, Athens, Greece
Evangelos Terpos , Meletios A. Dimopoulos , Mario Boccadoro , Sosana Delimpasi , Meral Beksac , Eirini Katodritou , Philippe Moreau , Luca Baldini , Argiris Symeonidis , Jelena Bila , Albert Oriol , Maria-Victoria Mateos , Hermann Einsele , Ioannis Orfanidis , Katharine S. Gries , John Fastenau , Tobias Kampfenkel , Yanping Qiu , Himal Amin , Pieter Sonneveld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03180736
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8046)
DOI
10.1200/JCO.2021.39.15_suppl.8046
Abstract #
8046
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.
First Author: Donna Ellen Reece
Poster
2020 ASCO Virtual Scientific Program
Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
First Author: Nizar J. Bahlis
Poster
2020 ASCO Virtual Scientific Program
Once weekly selinexor, carfilzomib, and dexamethasone (SKd) in patients with relapsed/refractory multiple myeloma (MM).
First Author: Cristina Gasparetto
Poster
2018 ASCO Annual Meeting
Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure.
First Author: David Samuel DiCapua Siegel